Relay Therapeutics beats Q4 revenue expectations

Relay Therapeutics

26/02/2026 21:38

Overview

Clinical-stage precision medicine firm's Q4 revenue beat analyst expectations

Net loss for Q4 came in narrower than analysts' expectations

Company ended 2025 with $555 mln in cash, funding expected into 2029

Outlook

Relay Therapeutics expects initial Phase 1 data for vascular anomalies in 1H 2026

Company plans to present Phase 1/2 breast cancer data at ESMO TAT in March 2026

Relay Therapeutics to announce breast cancer triplet data and Phase 3 plans in 2026

Result Drivers

REVENUE INCREASE - Revenue rose due to licensing agreement with Elevar Therapeutics, contributing to a beat on analyst expectations

R&D EXPENSES - R&D expenses decreased due to strategic streamlining and reduced costs on certain projects, offset by increased trial costs

G&A EXPENSES - Decreased G&A expenses due to lower stock compensation and employee costs contributed to narrower net loss

Company press release: ID:nGNXnG1fm

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$7 mln
$4.97 mln (9 Analysts)
Q4 EPS
-$0.32
Q4 Net Income
Beat
-$54.89 mln
-$68.09 mln (7 Analysts)
Q4 Basic EPS
-$0.32
Q4 Operating Expenses
$67.63 mln
Q4 Operating Income
-$60.63 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Relay Therapeutics Inc is $14.00, about 51.8% above its February 25 closing price of $9.22

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)